✨ Your Portfolio is fetched and updated from zerodha.
Mid Pharmaceuticals

Glenmark Pharmaceuticals Ltd.

GLENMARK

Market Cap
₹47,119 Cr.
P/E
45.00

Glenmark Pharmaceuticals Ltd.

  • Glenmark Pharma
  • Glaxosmithkline Phar
  • Alkem Laboratories
  • TJI Pharma
FAQs on Glenmark Pharmaceuticals Ltd. Shareprice

Glenmark Pharma has given better returns compared to its competitors.
Glenmark Pharma has grown at ~26.9% over the last 4yrs while peers have grown at a median rate of 10.74%

Yes, Glenmark Pharma is expensive.
Latest PE of Glenmark Pharma is 45.0, while 3 year average PE is 16.58.
Also latest EV/EBITDA of Glenmark Pharma is 20.25 while 3yr average is 13.41.

View FAQ's On Business
Growth Table
  • Glenmark Pharmaceuticals Ltd.
  • Glaxosmithkline Phar
  • Alkem Laboratories
Balance Sheet
  • Glenmark Pharmaceuticals Ltd.
  • Glaxosmithkline Phar
  • Alkem Laboratories
Balance Sheet Snapshot
No data available.
Fund Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
*Data is as of latest FY end
Profit & Loss
  • Glenmark Pharmaceuticals Ltd.
  • Glaxosmithkline Phar
  • Alkem Laboratories
Cash Flow
  • Glenmark Pharmaceuticals Ltd.
  • Glaxosmithkline Phar
  • Alkem Laboratories
Cash Flow Analysis
  • 1y
  • 3y
  • 5y
  • 10y
  • Increase
  • Decrease
  • Total
No data available.
Ratios
= Dominant Factor
  • Glenmark Pharmaceuticals Ltd.
  • Glaxosmithkline Phar
  • Alkem Laboratories
Quarterly Results
  • Glenmark Pharmaceuticals Ltd.
  • Glaxosmithkline Phar
  • Alkem Laboratories
Reverse DCF
locked
Cr
locked
5 YEAR
locked 5
10 YEAR
locked 10
20 YEAR
locked 20
Implied Growth Rate over a 5 year period*
Implied Growth Rate over a 10 year period*
Implied Growth Rate over a 20 year period*
*Implied Growth calculated using Newton-Raphson method.
Learn how to use Reverse DCF
FAQs on Glenmark Pharmaceuticals Ltd. Financials

Balance sheet of Glenmark Pharma is strong.
But short term working capital might become an issue for this company.

Yes, The net debt of Glenmark Pharma is increasing.
Latest net debt of Glenmark Pharma is ₹489 Crs as of Mar-25.
This is greater than Mar-24 when it was -₹2,327.34 Crs.

The profit is oscillating.
The profit of Glenmark Pharma is ₹1,047 Crs for TTM, -₹1,501.67 Crs for Mar 2024 and ₹297 Crs for Mar 2023.

The company seems to be paying a very low dividend.
Investors need to see where the company is allocating its profits.
Glenmark Pharma latest dividend payout ratio is 23.73% and 3yr average dividend payout ratio is 15.61%

Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Cash & Short Term Investments, Capital Work in Progress, Inventory, Short Term Loans & Advances

View FAQ's On Shareholding
Ideas Dashboard
Timeline
Watchlist
Portfolio
Alerts
Research
Stock Screener
Market
Raw Material
Data feed provided by Accord Fintech